InterCure Ltd. (NASDAQ:INCR - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 46,500 shares, a growth of 96.2% from the December 31st total of 23,700 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 41,200 shares, the short-interest ratio is currently 1.1 days.
InterCure Trading Down 0.4 %
Shares of INCR stock traded down $0.01 during mid-day trading on Wednesday, reaching $1.68. The stock had a trading volume of 25,187 shares, compared to its average volume of 14,133. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.78 and a quick ratio of 1.15. InterCure has a one year low of $1.17 and a one year high of $3.72. The firm's 50 day simple moving average is $1.54 and its 200 day simple moving average is $1.78.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of INCR. Renaissance Technologies LLC lifted its holdings in shares of InterCure by 30.9% during the 2nd quarter. Renaissance Technologies LLC now owns 45,300 shares of the company's stock worth $91,000 after acquiring an additional 10,700 shares during the period. Jane Street Group LLC acquired a new stake in InterCure during the third quarter valued at approximately $49,000. Finally, Virtu Financial LLC bought a new stake in shares of InterCure in the 3rd quarter valued at approximately $43,000. 8.34% of the stock is owned by institutional investors.
InterCure Company Profile
(
Get Free Report)
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider InterCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InterCure wasn't on the list.
While InterCure currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
